Cognition enhancement by the acetylcholine releaser DuP 996

DuP 996, 3,3,‐Bis(4‐pyridinylmethyl)‐1‐phenylindolin‐2‐one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01–0.1 mg/kg s.c. D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug development research 1990, Vol.19 (3), p.301-314
Hauptverfasser: Cook, Leonard, Nickolson, Victor J., Steinfels, George F., Rohrbach, Kenneth W., Denoble, Victor J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 314
container_issue 3
container_start_page 301
container_title Drug development research
container_volume 19
creator Cook, Leonard
Nickolson, Victor J.
Steinfels, George F.
Rohrbach, Kenneth W.
Denoble, Victor J.
description DuP 996, 3,3,‐Bis(4‐pyridinylmethyl)‐1‐phenylindolin‐2‐one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01–0.1 mg/kg s.c. DuP 996 protected against a hypoxia‐induced passive avoidance deficit in rats. In active avoidance procedures, DuP 996 enhanced acquisition of responses: in rats, at doses between 0.085 and 0.85 mg/kg s.c. and 0.25 and 0.85 mg/kg p.o.; in mice, at doses between 0.85 and 2.5 mg/kg s.c. These effects occurred without any alteration of sensitivity to foot‐shock. In addition, Dup 996 prevented a CO2‐induced retention deficit of a passive avoidance response when administered prior to acquisition testing. In a test for acquisition of lever pressing for food in the rat, DuP 996 increased the proportion of animals acquiring this response. Thus, DuP 996 was active in both the shock‐ and appetitive‐motivated procedures and was shown to enhance performance levels when administered post‐training as well as before training trials. These results suggest that DuP 996 may be useful in the treatment of cognition dysfunction.
doi_str_mv 10.1002/ddr.430190308
format Article
fullrecord <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_ddr_430190308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_LXS164H9_7</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3518-a5074cdd6fa9ecbda80ce0357baa1cbc5cf3fd45469da9b2096a3f8a50cec6b83</originalsourceid><addsrcrecordid>eNp9jztPwzAUhS0EEqUwsmdhTLl-xLHFhFraIlWAeAg2y3FuaCBNKjsI8u8JalWYmO7ynXPuR8gphREFYOd57keCA9XAQe2RAQWtYsa03icDYCmLBdf0kByF8AZAqVBqQC7GzWtdtmVTR1gvbe1whXUbZV3ULjGyDtuucsumKmuMPFZoA_po8nEXaS2PyUFhq4An2zskT9Orx_E8XtzOrseXi9jxhKrYJpAKl-eysBpdllsFDoEnaWYtdZlLXMGLXCRC6tzqjIGWlheqjzl0MlN8SOJNr_NNCB4Ls_blyvrOUDA_5qY3Nzvznj_b8GsbnK0K32uV4TekmdCSsZ5LN9xnWWH3f6mZTO7_Lmw_KkOLX7uk9e9GpjxNzPPNzCxeHqgUc21S_g2PiXiR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cognition enhancement by the acetylcholine releaser DuP 996</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Cook, Leonard ; Nickolson, Victor J. ; Steinfels, George F. ; Rohrbach, Kenneth W. ; Denoble, Victor J.</creator><creatorcontrib>Cook, Leonard ; Nickolson, Victor J. ; Steinfels, George F. ; Rohrbach, Kenneth W. ; Denoble, Victor J.</creatorcontrib><description>DuP 996, 3,3,‐Bis(4‐pyridinylmethyl)‐1‐phenylindolin‐2‐one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01–0.1 mg/kg s.c. DuP 996 protected against a hypoxia‐induced passive avoidance deficit in rats. In active avoidance procedures, DuP 996 enhanced acquisition of responses: in rats, at doses between 0.085 and 0.85 mg/kg s.c. and 0.25 and 0.85 mg/kg p.o.; in mice, at doses between 0.85 and 2.5 mg/kg s.c. These effects occurred without any alteration of sensitivity to foot‐shock. In addition, Dup 996 prevented a CO2‐induced retention deficit of a passive avoidance response when administered prior to acquisition testing. In a test for acquisition of lever pressing for food in the rat, DuP 996 increased the proportion of animals acquiring this response. Thus, DuP 996 was active in both the shock‐ and appetitive‐motivated procedures and was shown to enhance performance levels when administered post‐training as well as before training trials. These results suggest that DuP 996 may be useful in the treatment of cognition dysfunction.</description><identifier>ISSN: 0272-4391</identifier><identifier>EISSN: 1098-2299</identifier><identifier>DOI: 10.1002/ddr.430190308</identifier><identifier>CODEN: DDREDK</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Alzheimer's disease ; Biological and medical sciences ; cholinergic ; Cholinergic system ; dementia ; learning and memory ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments</subject><ispartof>Drug development research, 1990, Vol.19 (3), p.301-314</ispartof><rights>Copyright © 1990 Wiley‐Liss, Inc.</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3518-a5074cdd6fa9ecbda80ce0357baa1cbc5cf3fd45469da9b2096a3f8a50cec6b83</citedby><cites>FETCH-LOGICAL-c3518-a5074cdd6fa9ecbda80ce0357baa1cbc5cf3fd45469da9b2096a3f8a50cec6b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fddr.430190308$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fddr.430190308$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,4010,27900,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19249622$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Cook, Leonard</creatorcontrib><creatorcontrib>Nickolson, Victor J.</creatorcontrib><creatorcontrib>Steinfels, George F.</creatorcontrib><creatorcontrib>Rohrbach, Kenneth W.</creatorcontrib><creatorcontrib>Denoble, Victor J.</creatorcontrib><title>Cognition enhancement by the acetylcholine releaser DuP 996</title><title>Drug development research</title><addtitle>Drug Dev. Res</addtitle><description>DuP 996, 3,3,‐Bis(4‐pyridinylmethyl)‐1‐phenylindolin‐2‐one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01–0.1 mg/kg s.c. DuP 996 protected against a hypoxia‐induced passive avoidance deficit in rats. In active avoidance procedures, DuP 996 enhanced acquisition of responses: in rats, at doses between 0.085 and 0.85 mg/kg s.c. and 0.25 and 0.85 mg/kg p.o.; in mice, at doses between 0.85 and 2.5 mg/kg s.c. These effects occurred without any alteration of sensitivity to foot‐shock. In addition, Dup 996 prevented a CO2‐induced retention deficit of a passive avoidance response when administered prior to acquisition testing. In a test for acquisition of lever pressing for food in the rat, DuP 996 increased the proportion of animals acquiring this response. Thus, DuP 996 was active in both the shock‐ and appetitive‐motivated procedures and was shown to enhance performance levels when administered post‐training as well as before training trials. These results suggest that DuP 996 may be useful in the treatment of cognition dysfunction.</description><subject>Alzheimer's disease</subject><subject>Biological and medical sciences</subject><subject>cholinergic</subject><subject>Cholinergic system</subject><subject>dementia</subject><subject>learning and memory</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><issn>0272-4391</issn><issn>1098-2299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNp9jztPwzAUhS0EEqUwsmdhTLl-xLHFhFraIlWAeAg2y3FuaCBNKjsI8u8JalWYmO7ynXPuR8gphREFYOd57keCA9XAQe2RAQWtYsa03icDYCmLBdf0kByF8AZAqVBqQC7GzWtdtmVTR1gvbe1whXUbZV3ULjGyDtuucsumKmuMPFZoA_po8nEXaS2PyUFhq4An2zskT9Orx_E8XtzOrseXi9jxhKrYJpAKl-eysBpdllsFDoEnaWYtdZlLXMGLXCRC6tzqjIGWlheqjzl0MlN8SOJNr_NNCB4Ls_blyvrOUDA_5qY3Nzvznj_b8GsbnK0K32uV4TekmdCSsZ5LN9xnWWH3f6mZTO7_Lmw_KkOLX7uk9e9GpjxNzPPNzCxeHqgUc21S_g2PiXiR</recordid><startdate>1990</startdate><enddate>1990</enddate><creator>Cook, Leonard</creator><creator>Nickolson, Victor J.</creator><creator>Steinfels, George F.</creator><creator>Rohrbach, Kenneth W.</creator><creator>Denoble, Victor J.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1990</creationdate><title>Cognition enhancement by the acetylcholine releaser DuP 996</title><author>Cook, Leonard ; Nickolson, Victor J. ; Steinfels, George F. ; Rohrbach, Kenneth W. ; Denoble, Victor J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3518-a5074cdd6fa9ecbda80ce0357baa1cbc5cf3fd45469da9b2096a3f8a50cec6b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Alzheimer's disease</topic><topic>Biological and medical sciences</topic><topic>cholinergic</topic><topic>Cholinergic system</topic><topic>dementia</topic><topic>learning and memory</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cook, Leonard</creatorcontrib><creatorcontrib>Nickolson, Victor J.</creatorcontrib><creatorcontrib>Steinfels, George F.</creatorcontrib><creatorcontrib>Rohrbach, Kenneth W.</creatorcontrib><creatorcontrib>Denoble, Victor J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Drug development research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cook, Leonard</au><au>Nickolson, Victor J.</au><au>Steinfels, George F.</au><au>Rohrbach, Kenneth W.</au><au>Denoble, Victor J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognition enhancement by the acetylcholine releaser DuP 996</atitle><jtitle>Drug development research</jtitle><addtitle>Drug Dev. Res</addtitle><date>1990</date><risdate>1990</risdate><volume>19</volume><issue>3</issue><spage>301</spage><epage>314</epage><pages>301-314</pages><issn>0272-4391</issn><eissn>1098-2299</eissn><coden>DDREDK</coden><abstract>DuP 996, 3,3,‐Bis(4‐pyridinylmethyl)‐1‐phenylindolin‐2‐one, a potent in vitro and in vivo releaser of acetylcholine (ACh), dopamine (DA), and serotonin (5HT) in rat brain, significantly enhanced the performance of rats and mice in several behavioral test procedures. At doses of 0.01–0.1 mg/kg s.c. DuP 996 protected against a hypoxia‐induced passive avoidance deficit in rats. In active avoidance procedures, DuP 996 enhanced acquisition of responses: in rats, at doses between 0.085 and 0.85 mg/kg s.c. and 0.25 and 0.85 mg/kg p.o.; in mice, at doses between 0.85 and 2.5 mg/kg s.c. These effects occurred without any alteration of sensitivity to foot‐shock. In addition, Dup 996 prevented a CO2‐induced retention deficit of a passive avoidance response when administered prior to acquisition testing. In a test for acquisition of lever pressing for food in the rat, DuP 996 increased the proportion of animals acquiring this response. Thus, DuP 996 was active in both the shock‐ and appetitive‐motivated procedures and was shown to enhance performance levels when administered post‐training as well as before training trials. These results suggest that DuP 996 may be useful in the treatment of cognition dysfunction.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/ddr.430190308</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-4391
ispartof Drug development research, 1990, Vol.19 (3), p.301-314
issn 0272-4391
1098-2299
language eng
recordid cdi_crossref_primary_10_1002_ddr_430190308
source Wiley Online Library Journals Frontfile Complete
subjects Alzheimer's disease
Biological and medical sciences
cholinergic
Cholinergic system
dementia
learning and memory
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
title Cognition enhancement by the acetylcholine releaser DuP 996
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A31%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognition%20enhancement%20by%20the%20acetylcholine%20releaser%20DuP%20996&rft.jtitle=Drug%20development%20research&rft.au=Cook,%20Leonard&rft.date=1990&rft.volume=19&rft.issue=3&rft.spage=301&rft.epage=314&rft.pages=301-314&rft.issn=0272-4391&rft.eissn=1098-2299&rft.coden=DDREDK&rft_id=info:doi/10.1002/ddr.430190308&rft_dat=%3Cistex_cross%3Eark_67375_WNG_LXS164H9_7%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true